Lysophosphatidic acid (LPA) is a small, bioactive phospholipid that mediates multiple cellular responses, including proliferation, differentiation, motility, and survival in both normal physiology and disease. The extracellular actions of LPA are mediated primarily through its interaction with five G protein-coupled receptors which include LPA1(EDG2), LPA2(EDG4), LPA3(EDG7), LPA4 (GPR23 or P2Y9) and LPA5 (GPR92). Among them, LPA1 (EDG2) is most widely expressed in normal tissue during growth and development. After LPA stimulation, LPA1 (EDG2) couples to Gi and G12/13 and was reported to play an important role in CND development and related to initiation of neuropathic pain.
|Product Description||Frozen membranes from RH7777 cells expressing recombinant human EDG2 Lysophosphatidic Acid receptors.|
|Therapeutic Area||cancer, pain & inflammation|
|Related Services||Membrane Preparation, GPCR Screening|
|Genbank Accession Number||NM_001401|
|References||Inoue, M., et al., (2004) Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med. 10(7):712-8.
Takuwa, Y., et al (2002) The Edg family G protein-coupled receptors for lysophospholipids: their signaling properti
|Recommended Assay Conditions||Refer to product specification sheet for details|
|Storage and Packaging|
|Packaging||0.4 mL of membrane suspension in storage buffer (20 mM Hepes, 1 mM EDTA, 50mM NaCl, 10% sucrose; pH 7.4) at a protein concentration of 5 mg/mL|
|Storage Recommendation||Storage at -80oC is recommended. Repeated freeze-thawing of this product is not recommended.|
|Specification Sheet||Download PDF Document|